KKPCF.US Kaken Pharmaceutical Co. Ltd
- Market cap
- USD 985M
- P/E
- -
- P/B
- 1.02x
- ROE
- 10.3%
- Dividend yield
- 4.60%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is KKPCF.US undervalued?
Graham numberThe Graham number of Kaken Pharmaceutical Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kaken Pharmaceutical Co. Ltd fundamental analysis
No fundamental analysis for Kaken Pharmaceutical Co. Ltd yet.
Kaken Pharmaceutical Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kaken Pharmaceutical Co. Ltd
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc …
Full company profileKaken Pharmaceutical Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kaken Pharmaceutical Co. Ltd annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 102B | 98.4B | 94.2B | 89.2B | 75.0B | 76.0B | 73.0B | 72.0B | 94.0B | 77.4B | 97.9B |
| Gross Profit | 57.5B | 56.0B | 53.8B | 50.5B | 40.9B | 41.6B | 39.6B | 38.5B | 58.5B | 39.5B | 61.5B |
| Operating Income | 30.7B | 27.5B | 24.6B | 26.5B | 17.8B | 17.1B | 8.00B | 9.51B | 21.0B | -905M | 20.2B |
| EBITDA | 32.6B | 29.8B | 27.6B | 29.3B | 21.0B | 16.4B | 9.40B | 12.6B | 22.0B | 2.42B | 24.2B |
| Net Income | 22.0B | 19.0B | 17.8B | 19.4B | 13.4B | 9.55B | 5.44B | 8.03B | 13.9B | 2.16B | 15.9B |
| EPS | 537 | 471 | 446 | 495 | 347 | 251 | 145 | 213 | 365 | 57 | 419 |
| Balance Sheet | |||||||||||
| Total Assets | 135B | 152B | 156B | 158B | 163B | 165B | 166B | 172B | 190B | 179B | 189B |
| Total Liabilities | 32.4B | 38.5B | 34.9B | 29.4B | 27.1B | 26.9B | 29.5B | 27.9B | 37.8B | 30.8B | 35.0B |
| Shareholders' Equity | 103B | 114B | 121B | 128B | 136B | 138B | 136B | 144B | 153B | 149B | 154B |
| Cash & Short-term Investments | 43.8B | 52.7B | 58.6B | 73.3B | 77.3B | 74.6B | 74.3B | 65.3B | 70.1B | 51.0B | 59.8B |
| Total Debt | 3.88B | 3.88B | 3.88B | 3.85B | 3.85B | 3.85B | 3.85B | 3.85B | 3.85B | 3.87B | 3.87B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 15.3B | 21.7B | 21.1B | 27.5B | 14.4B | 13.3B | 9.25B | 2.58B | 29.8B | -11.1B | - |
| Capital Expenditure | 2.35B | 1.89B | 2.13B | 2.20B | 2.29B | 3.26B | 2.21B | 2.17B | 4.39B | 3.01B | 0.00 |
| Free Cash Flow | 13.0B | 19.8B | 19.0B | 25.3B | 12.1B | 10.1B | 7.05B | 410M | 25.4B | -14.2B | - |
| Ratios | |||||||||||
| ROE | 21.4% | 16.7% | 14.7% | 15.1% | 9.8% | 6.9% | 4.0% | 5.6% | 9.1% | 1.5% | 10.3% |
| ROA | 16.3% | 12.5% | 11.4% | 12.3% | 8.2% | 5.8% | 3.3% | 4.7% | 7.3% | 1.2% | 8.4% |
| Net Profit Margin | 21.6% | 19.3% | 18.9% | 21.7% | 17.9% | 12.6% | 7.5% | 11.1% | 14.8% | 2.8% | 16.2% |
| Debt to Equity | 0.04x | 0.03x | 0.03x | 0.03x | 0.03x | 0.03x | 0.03x | 0.03x | 0.03x | 0.03x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kaken Pharmaceutical Co. Ltd dividends
- Dividend yield
- 4.60%
- Forward dividend
- 1.19 USD
- Payout ratio
- 303.1%
- Ex-dividend date
- Mar 31, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 6.54B | 172 | 303.1% |
| 2025 | JPY 7.20B | 189 | 51.6% |
| 2024 | JPY 5.66B | 150 | 70.5% |
| 2023 | JPY 5.65B | 150 | 103.8% |
| 2022 | USD 5.71B | 150 | 59.8% |
| 2021 | USD 5.81B | 151 | 43.3% |
| 2020 | USD 5.90B | 151 | 30.4% |
| 2019 | USD 6.00B | 150 | 33.8% |
| 2018 | USD 6.09B | 150 | 32.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:2 on Sep 28, 2015.
Who owns Kaken Pharmaceutical Co. Ltd
- Insiders 11.30%
- Institutions 22.56%
- Public & others 66.15%
- Shares outstanding 37.9M
- Free float 34.7M
Kaken Pharmaceutical Co. Ltd company profile
- Company name
- Kaken Pharmaceutical Co. Ltd
- Ticker
- KKPCF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,114
- Fiscal year end
- March
- Address
- 28-8, Honkomagome 2-chome, Tokyo, Japan, 113-8650
- Phone
- 81 3 5977 5007
- Website
- kaken.co.jp
About Kaken Pharmaceutical Co. Ltd
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins, that are used as fungicides; Pentoxazone and Metamifop rice herbicides; Salinomycin, an anti-coccidial feed additive for chickens; and Uroston, a urinary stone dissolution and elimination acceleration agent for cattle. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001, which is in phase III clinical trial for the treatment of refractory vascular malformations; Seladelpar that is in phase III clinical trial for primary biliary cholangitis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia. Further, it is involved in the rental of Bunkyo Green Court. The company has a collaboration and licensing agreement with Alumis Inc. to develop, manufacture, and commercialize ESK-001, a selective oral tyrosine kinase 2 (TYK2) inhibitor for dermatology indications in Japan. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
Kaken Pharmaceutical Co. Ltd management
10- Mr. Hiroyuki HoriuchiChairman, President & Representative Director · born 1962
- Mr. Tomohiro Takaya Ph.D.General Manager of Legal Affairs & Intellectual Property Department
- Gaku KametsuGeneral Manager of Corporate Communications Department
- Mr. Tomoyuki KosekiChief Officer of Marketing & Sales Division
- Mr. Masashi SuzudoMD, Director of the Corporate Planning & Coordination Department and Director · born 1962
- Mr. Mitsuru WatanukiChief Officer of R&D Division and Director · born 1964
- Masaru OgawaHead of Pharmaceutical Affairs Dep. and Director of Regulatory Affairs Div.
- Tatsuhiro HaradaHead of Drug Research Center & CMC Center
- Mr. Keizo KimuraCorporate Officer, Chief Officer of Production Division & Chief of Shizuoka Factory
- Hideki KawabataHead of Clinical Development Department